News brief­ing: No­var­tis' Zol­gens­ma hits block­buster sta­tus, trig­ger­ing $80M mile­stone; Caris rais­es $310M for ge­nom­ic pro­fil­ing ex­pan­sion

No­var­tis re­port­ed that Zol­gens­ma earned $291 mil­lion in Q3, which puts the SMA gene ther­a­py square­ly in the block­buster cat­e­go­ry. That, in turn, is pay­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER